Cash flow data is largely unavailable beyond 2022Q4, when operating cash outflow of $23.0M exceeded the $3.1M net loss by 7.45x while $18.4M of buybacks consumed about 77% of that outflow, leaving the post-windfall cash trajectory unverified.
Compugen Ltd. (CGEN) cash flow statement — 27-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 |
|---|
| Cash from Operations | 0 | 31.63M | 49.6M | -35.89M | -34.11M | -22.69M | -28.32M | -27.89M | -13.29M | -30.66M | -19.82M | -25.61M | -11.15M | -6.44M | -10.85M | -9.25M | -4.28M | -7.45M | -10.01M | -8.41M | -9.93M | -11.11M | -12.2M | -5.57M | -9.08M | -9.5M | -6.14M | -5.76M |
| Operating CF Margin % | - | 43.47% | 178.02% | -107.25% | -454.84% | -378.18% | -1416% | - | -74.67% | - | -2783.57% | -276.03% | -90.14% | -181.43% | -4481.82% | 2181.37% | -383.77% | -2981.2% | -2962.13% | -4670.56% | -4620% | -1719.5% | -303% | -63.14% | -81.79% | -83.6% | -89.12% | -178.04% |
| Operating CF Growth % | 0% | -36.23% | 238.23% | -5.2% | -50.34% | 19.88% | -1.55% | -109.83% | 56.65% | -54.69% | 22.6% | -129.7% | -73.13% | 40.63% | -17.27% | -116.15% | 42.59% | 25.56% | -19.09% | 15.36% | 10.58% | 8.97% | -118.95% | 38.6% | 4.43% | -54.65% | -6.56% | - |
| Net Income | 35.19M | 35.34M | -14.23M | -18.75M | -33.69M | -34.2M | -29.7M | -27.34M | -22.6M | -37.07M | -31.51M | -20.16M | -11.09M | -14.08M | -13.63M | -12M | -7.2M | -3.84M | -12.51M | -12.11M | -13.02M | -13.98M | -13.72M | -11.44M | -12.2M | -15.14M | -13.4M | -8.13M |
| Depreciation & Amortization | 0 | 475K | 486K | 476K | 482K | 461K | 715K | 989K | 1.39M | 1.59M | 1.48M | 1.11M | 658K | 370K | 299K | 179K | 201K | 264K | 477K | 633K | 996K | 2.39M | 1.76M | 2.67M | 2.9M | 4.28M | 4.99M | 1.86M |
| Stock-Based Compensation | 0 | 0 | 3.02M | 3.55M | 4.33M | 4.28M | 2.77M | 2.41M | 2.17M | 2.63M | 3.08M | 3.77M | 3.63M | 3.54M | 2.47M | 3.4M | 2.34M | 1.53M | 1.8M | 0 | 0 | 0 | 786K | 786K | 2.59M | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | -12K | -135K | 52K | 0 | -383K | -279K | -2.67M | -2.94M | 643K | -126K | -419K | -3.85M | 117K | 0 | 0 | 0 | -786K | -786K | -2.59M | 0 | 0 | 0 |
| Other Non-Cash Items | -35.19M | 1.16M | -1.72M | -452K | 324K | -45K | 184K | -22K | 46K | -33K | 101K | -421K | 455K | -230K | -130K | -7K | 164K | -88K | 31K | 3.44M | 2.27M | 197K | 1.66M | 723K | 932K | 54K | 2.05M | 1.16M |
| Working Capital Changes | 0 | -5.35M | 62.05M | -20.71M | -5.55M | 6.82M | -2.28M | -3.79M | 5.65M | 2.21M | 7.4M | -9.62M | -2.13M | 6.91M | -499K | -691K | 641K | -1.46M | 71K | -370K | -181K | 287K | -1.9M | 2.47M | -702K | 1.32M | 220K | -657K |
| Change in Receivables | 0 | 360K | 59.93M | -61.11M | 2.46M | -333K | -2M | -142K | -179K | 422K | 7.8M | -7.8M | 1.03M | -1.1M | -112K | 43K | -21K | 58K | 222K | 0 | 0 | 0 | 1.61M | 1.61M | 81K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -3.82M | 3.5M | -954K | 247K | 518K | -1.17M | 152K | 202K | 0 | 734K | 213K | 0 | 0 | 0 | 0 | 0 | 80K | 80K | 23K | 42K | -5K | 165K |
| Change in Payables | 0 | 517K | -4.41M | 3.51M | -1.6M | 3.37M | 3.82M | -3.5M | 2.69M | 1.56M | -605K | 823K | 1.67M | 1.04M | -86K | -734K | 562K | -1.53M | 0 | 0 | 0 | 0 | -796K | -796K | 1.77M | 0 | 0 | 0 |
| Cash from Investing | 0 | 30M | -46.25M | 35.51M | 37.06M | 6.62M | -82.17M | 5.33M | -35.16M | 46.27M | 16.29M | 9.77M | -64.09M | -11.57M | 12.26M | -1.23M | -13.67M | 5.73M | 13.12M | 3.16M | 7.03M | 15.06M | 5.93M | 4.85M | 5.77M | -62.84M | -12.07M | -1.8M |
| Capital Expenditures | 0 | -306K | -118K | -172K | -487K | -292K | -166K | -155K | -158K | -385K | -2.6M | -3.12M | -1.9M | -328K | -1M | -96K | -46K | -48K | -120K | -205K | -161K | -862K | -1.44M | -2.33M | -1.43M | -2.77M | -2.03M | -1.8M |
| CapEx % of Revenue | 0% | 0.42% | 0.42% | 0.51% | 6.49% | 4.87% | 8.3% | - | 0.89% | - | 365.03% | 33.63% | 15.33% | 9.24% | 415.29% | -22.64% | 4.13% | 19.2% | 35.5% | 113.89% | 74.88% | 133.44% | 35.63% | 26.35% | 12.85% | 24.34% | 29.52% | 55.61% |
| Acquisitions | 0 | 1K | 0 | 0 | 0 | 0 | 44K | 382K | 2K | -46.66M | 0 | 423K | 2.31M | 3.6M | 0 | 232K | 25K | 185K | 0 | 1K | 82K | 0 | 0 | 30.2M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -329K | 0 | 2K | 3K | 0 | 0 | 2K | 46.66M | 84K | -534K | -491K | -50K | -42K | 639K | -47K | -96K | 14K | 7K | -11.96M | 409K | -7K | -1.28M | -19K | -30.64M | -32K | -3K |
| Cash from Financing | 0 | 10.6M | 554K | 3.08M | 353K | 16.84M | 108.46M | 25.93M | 28.4M | 201K | 2.46M | 972K | 72.13M | 30.39M | 9.11M | 9.02M | 10.11M | 12.21M | 295K | 295K | 665K | 178K | 2.73M | 3.34M | 161K | 104K | 87.45M | -939K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.04M | 0 | 0 | 0 | -958K |
| Equity Issued (Net) | 0 | 10.61M | 544K | 3.08M | 353K | 16.84M | 74.15M | 22.76M | 27.71M | 0 | 0 | 0 | 70.72M | 19.76M | 6.21M | 0 | 7.79M | 12.01M | 0 | 295K | 665K | 178K | 2.73M | 1.31M | 161K | 104K | 87.45M | 19K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -4K | 10K | 0 | 0 | 0 | 34.32M | 3.17M | 685K | 201K | 2.46M | 972K | 1.41M | 10.63M | 2.9M | 9.02M | 2.32M | 196K | 295K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.97M | 72.37M | 3.97M | 2.83M | 2.91M | 704K | -2.03M | 3.37M | -20.05M | 15.82M | -1.07M | -14.87M | -3.11M | 12.38M | 10.53M | -1.45M | -7.84M | 10.49M | 3.35M | -4.95M | -2.24M | 4.13M | -3.54M | 2.62M | -3.15M | -72.24M | 69.24M | -8.51M |
| Free Cash Flow | 0 | 31.33M | 49.49M | -36.06M | -34.6M | -22.98M | -28.49M | -28.04M | -13.45M | -31.04M | -22.42M | -28.73M | -13.04M | -6.77M | -11.85M | -9.35M | -4.33M | -7.5M | -10.13M | -8.61M | -10.09M | -11.97M | -13.64M | -7.9M | -10.5M | -12.26M | -8.18M | -7.56M |
| FCF Margin % | 0% | 43.05% | 177.6% | -107.77% | -461.33% | -383.05% | -1424.3% | - | -75.56% | - | -3148.6% | -309.66% | -105.47% | -190.67% | -4897.11% | 2204.01% | -387.89% | -3000.4% | -2997.63% | -4784.44% | -4694.88% | -1852.94% | -338.64% | -89.5% | -94.64% | -107.94% | -118.63% | -233.64% |
| FCF Growth % | - | -36.69% | 237.24% | -4.21% | -50.55% | 19.32% | -1.58% | -108.51% | 56.68% | -38.47% | 21.96% | -120.23% | -92.76% | 42.9% | -26.82% | -116.07% | 42.34% | 25.97% | -17.65% | 14.68% | 15.67% | 12.22% | -72.64% | 24.79% | 14.35% | -49.99% | -8.09% | - |
| FCF per Share | 0.00 | 0.33 | 0.55 | -0.41 | -0.40 | -0.27 | -0.36 | -0.44 | -0.24 | -0.61 | -0.44 | -0.57 | -0.27 | -0.17 | -0.33 | -0.27 | -0.13 | -0.26 | -0.36 | -0.30 | -0.36 | -0.43 | -0.50 | -0.30 | -0.40 | -0.47 | -0.59 | -0.54 |
| FCF Conversion (FCF/Net Income) | 0.00x | 0.90x | -3.49x | 1.91x | 1.01x | 0.66x | 0.95x | 1.02x | 0.59x | 0.83x | 0.63x | 1.27x | 1.00x | 0.46x | 0.80x | 0.77x | 0.59x | 1.95x | 0.80x | 0.69x | 0.76x | 0.79x | 0.89x | 0.49x | 0.74x | 0.63x | 0.46x | 0.71x |
| Interest Paid | 0 | 0 | 0 | 0 | 852K | 1.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying CGEN stock.
Compugen Ltd. (CGEN) generated $31.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Compugen Ltd. (CGEN) generated $31.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Compugen Ltd. (CGEN) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Unverified windfall cash conversion
Earnings-to-Cash Gap Widens Sharply
In Compugen's only reported cash flow quarter, operating cash outflow reached $23.0M against a net loss of $3.1M, an OCF-to-net income ratio of 7.45x. According to 2022Q4 filings, cash generation lagged earnings materially, though subsequent quarters lack cash flow disclosures.
The 7.45x ratio reads as a meaningful quality-of-earnings shortfall: cash outflow exceeded the accounting loss by roughly $20M, which may reflect working capital swings, prepaid R&D, or other accrual movements not visible on the loss line. Because nine subsequent quarters report no operating cash flow, investors cannot determine whether this disconnect persisted through the Q4 2025 profit quarter, leaving the conversion profile effectively unassessed for the current period.
FCF Path Obscured by Missing Data
Free cash flow stood at -$23.4M in 2022Q4, a -3.1% FCF margin, but every subsequent period through 2026Q2 reports unavailable cash flow figures. As reflected in Compugen's cash flow tables, the trajectory of cash burn beyond the single observed quarter cannot be reliably established.
With FCF confined to one data point, no defensible margin trend or growth comparison can be constructed against the reported net income path. The absence of cash figures spanning the Q4 2025 revenue spike means the cash durability of that event is untested, so the earnings trajectory and any inferred cash trajectory should be treated as decoupled until filings populate the gap.
Asset-Light Profile Limits Capital Intensity
Capital expenditure was only $351K in 2022Q4, equating to 4.7% of revenue, while depreciation and amortization of $54K confirms a minimal fixed-asset base. Based on Compugen's reported figures, sustaining-asset cash requirements appear modest relative to R&D outlays, though later-period capex data is unavailable.
Capex modestly exceeding D&A suggests the existing asset base is being replaced roughly in line with consumption, but both magnitudes are so small that capital intensity is effectively negligible next to the $6-8M quarterly R&D spend identified elsewhere in the dataset. This profile implies cash preservation for Compugen hinges almost entirely on operating expense discipline rather than investment decisions, which concentrates the burden on pipeline spending choices.
Buybacks Funded Amid Operating Burn
Compugen repurchased $18.4M of shares in 2022Q4 while operations consumed $23.0M of cash and no dividends were paid, an unusual combination for a loss-making biotech. According to 2022Q4 disclosures, the buyback absorbed roughly 77% of operating outflow, implying reliance on balance sheet resources.
Returning capital while generating negative operating cash flow suggests the company drew on existing balances or external funding to repurchase shares, a choice that may have prioritized shareholder return over pipeline runway. Since no repurchase, dividend, or acquisition activity is disclosed in any later quarter, this single data point offers limited evidence on whether capital allocation priorities shifted after the Q4 2025 cash event.
Cumulative Losses Outpaced by Cash Burn
Across the ten observed quarters, cumulative net income approximates -$11.0M, yet the single quarter carrying operating cash flow data already shows a $23.0M outflow. Per Compugen's statements, the reported earnings record may understate true cash consumption, though full-period OCF data remains unavailable.
The one observable operating cash outflow already exceeds the cumulative accounting loss across all ten periods, suggesting reported results may not capture the full cash cost of sustaining the business. Because operating cash flow is unavailable for the $56.8M Q4 2025 profit quarter, the divergence between that reported gain and actual cash realization cannot be quantified, which is arguably the most consequential gap in this dataset.
SBC and Gain Recognition Cloud Cash View
Stock-based compensation of $4.3M in 2022Q4 exceeded that quarter's $3.1M net loss, signaling dilution that cash flow presentation may understate. Per Compugen's filings, the $56.8M Q4 2025 gain lacks any corresponding cash flow entry, leaving its cash realization unverified in the dataset.
SBC exceeding the reported loss indicates dilution is operating as a genuine economic cost that the statements present inconsistently, since the cash flow statement classifies it as a non-cash addback while existing shareholders absorb the equity reduction. The Q4 2025 gain likewise dominates cumulative earnings with no cash flow line confirming conversion to cash, so any inferred improvement in liquidity from that quarter warrants independent verification against disclosed cash and investment balances.